Kathleen Moore, MD, on the Key Takeaways of 3 Clinical Trials Examining Niraparib in BRCA-Mutant Ovarian Cancer

Video

Kathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Kathleen Moore, MD, director of the Oklahoma TSET Phase I Program and an associate professor of the Section of Gynecologic Oncology at The University of Oklahoma College of Medicine, to discuss key takeaways from 3 clinical trials that examined niraparib (Zejula) in BRCA-mutant ovarian cancer.

The analysis assessed the results of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016), ENGOT-OV16/NOVA (NCT01847274), and NORA (NCT03705156) trials, which examined the use of maintenance niraparib in the frontline and later-line settings of advanced ovarian, fallopian tube, or primary peritoneal cancer.

Transcript:

We are looking at 3 relatively large studies. We are a talking about approximately 1500 women who participated in PRIMA in the frontline, and NOVA and NORA in the [later]-line [setting]. About 1000 patients were treated with niraparib. One of the take-home [messages] is that we do not see any big or meaningful differences in terms of the toxicity profile when you move PARP [inhibitors] to the frontline, as opposed to using [them] as second-line maintenance. That is important. Safety is important in both settings. But it is important because in the frontline, we still do have the potential to cure. Carboplatin alone has an unacceptably low, but present, rate of long-term [median] disease-free survival of 7 to 10 years for advanced stage of cancer.

Reference

Gonzalez Martin A, Matulonis UA, Korach J, et al. Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: results from three phase 3 niraparib trials. J Clin Oncol. 2021;39(suppl 15):5518. doi:10.1200/JCO.2021.39.15_suppl.5518

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content